ep op dilut data report non-gaap
revenu million data report non-gaap
valu usd unless otherwis note
jakafi continu perform
view good modest sale beat continu
jakafi demand growth help share justifi bounc back recent
weak continu progress emerg derm/inflamm
franchis price target increas slightli fundament remain
solid though fewer key catalyst year view around reward/
risk addit gvhd readout high medicar exposur potenti
creat perceiv uncertainti near-term around out-year revenu
tail would wait add posit signific pipelin
slight beat jakafi sale driven demand jakafi sale
slightli our/con est growth qoq
addit detail driven continu mf pv demand
growth well tick hospit shipment reflect gvhd order
inventori hospit stock overal signific impact
guidanc updat previou lower bound
believ achiev expect growth
year though given note part exposur jakafi
evolv hc polici propos could caus perceiv uncertainti
long-term opportun
opex control remain good continu flexibl bd non-gaap
 estimate non-gaap sg
estimate opex guidanc
sg reiter believ cash
hand provid flexibl particularli compani weigh option
derm franchis build infrastructur vs
partner potenti in-licens mid-stag asset complement
oncolog portfolio
reveal ph iii trial design topic rux vitiligo maxim po
though opportun reli expand market ph iii program
consist two studi test highest effect
ph ii dose bid vs vehicl week primari
endpoint strong activ endpoint ph ii vs
placebo support high po believ
import expand vitiligo market believ vitiligo patient
current seek treatment well work price differenti vs
atop derm order solidifi topic rux opportun current
estimate out-year sale vitiligo market expans could
present signific upsid probability-adjust out-year
limit addit pipelin updat continu page
price prior trade day market close estimate unless otherwis note
bloomberg capit market estim upside/downside/target
base case assum jakafi sale exceed
 long term driven continu growth core market
probabl success new indic gvhd
et assum probability-adjust out-year
baricitinib royalti topic ruxolitinib
pemigatinib itacitinib out-year probability-
dcf discount rate termin growth
posit phase data jakafi et gvhd extens
jakafi life cycl next-gen combo better-than-
expect success within earlier-stag pipelin
acquisit big pharma would constitut upsid
scenario base dcf analysi would suggest
upsid valu
erod price power jakafi poor perform
earlier-stag pipelin clinic regulatori setback
jakafi combin would constitut downsid scenario
case dcf would suggest downsid valu
jakafi consider long-term potenti
sale limit downsid risk commerci execut
support strong revenu foundat compani
long term though life-cycl extens effort like
continu come increas focu given concern
patent cliff compani one
deeper cancer-focus pipelin biotech reflect strong
drug discoveri engin busi develop expertis
competit space make difficult pinpoint next first-
in-class blockbust pipelin somewhat
increas perceiv risk inflamm franchis due
question safeti gvhd moder indic
view fewer opportun addit near-term valu
inflect current level
posit high opportun jakafi driven growth
exist mf/pv indic long-term opportun et
gvhd strong price power construct partner
good commerci execut deep pipelin cancer
inflammation-focus asset potenti drive long-term
revenu multipl strateg option improv busi
effici unlock valu driven strong rel low-
risk cash flow leverag commerci infrastructur
consider pipelin breadth spend
risk oncolog rheumatolog space
competit farther behind larger compani
approach make import
compani differenti substanti efficacy/safeti
patent expiri time frame life-cycl
extens strategi depend early-stag
pim inhibitor may offer accept
efficacy/safeti alon combo jakafi drug price
potenti catalyst result reach ph iii
studi full approv acut gvhd file chronic
gvhd result studi itacitinib
treatment-na acut gvhd addit data
pemigatinib cholangiocarcinoma
continu pg
limit addit pipelin updat expect read
jakafi vs bat acut chronic steroid-refractori gvhd addit
trial assess itacitinib gvhd also expect
believ could potenti expand opportun meaning indic posit
updat year includ updat data well addit ph iii
atop derm data olumi continu expect signific year
pipelin topic rux ad readout updat jakafi life-cycl
producteventtimelinejakafiresult acut ph iii studi file full approv acut chronic ph iii studi snda file chronic addit combin strategi pim et trial top-lin data ph iii breeze-ad ph iii studi true-v ph iii trial ph iii true-ad trial ph iii treatment-nav acut gvhd data readout ph ii open-label studi low-dos rux combo ph ii cholangiocarcinoma read nda submiss ph ii complet enrol bladder cancer w/ continu dosingbi data snda file ph iii clinic trial bladder pivot tumor-agnost studi fgf/fgfr mutat solid tumorsbi nda submiss bladder cancer trial readout monotherapi data fl margin zone mantl cell nv cmet nda submiss alk-cmet amplifi ab proof-of-concept data combin checkpoint data combin checkpoint gitr proof-of-concept data combin checkpoint oral inhibitor initi ph pk/pd mru initi data ph readout monotherapi msi-high endometri cancer readout monotherapi anal ruxolitinib exhibit pipelin
drug/target partner/mechan indicationstatusjakafi nv mf pv gvhd etmarket mf pvolumi ra ad sle alopeciamarket eu japan ra phase topic ruxolitinibatop dermat vitiligophas enter phase itacitinib uc phase phase iicapmatinib nv cmet nsclcphase iipemigatinib cholangiocarcinoma bladder cancer mpnsphase iiparsaclisib iiepacadostatlung cancer epa pembro phase suppurativaphas combin therapi oncolog monotherapyent phase carcinomaphas sclcphase pim advanc malignanciesphas arg solid tumorsphas gitr solid tumorsphas tumorsphas ab cancerphas ab cancerphas dual inhibitor cancerphas oral inhibitor cancerphas mru cancerphas ipipelin exhibit incom statement
incom statement thousand except share royalties- net eu royalti probability-adjust revenu probability-adjust ruxolitinib revenu probabilty-adjust revenu probability-adjust pipelin revenu prob-adjust product cost incom net pre-tax benefit incom incom per share outstand share outstand biotechnolog
price target base dcf discount inci futur cash flow annual
termin growth rate begin jakafi patent expiri probability-
weight potenti favor strateg altern price target support sector
risk rate price target
downsid risk includ greater-than-expect slow jakafi use myelofibrosi
polycythemia vera inabl obtain regulatori approv pemigatinib itacitinib
topic ruxolitinib failur extend jakafi life cycl new competit entrant price
pressur jakafi olumi emerg safeti concern market product
limit efficaci signal within earlier-stag pipelin upsid risk includ better
expect uptak jakafi olumi approv higher-dos olumi develop
strategi meaning extend jakafi life cycl potenti execut
biotechnolog compani focus develop commerci
deep pipelin intern discov small molecul drug candid oncolog
inflammatori indic lead product jakafi ruxolitinib inhibitor market
myelofibrosi mf polycythemia vera pv addit acquisit ariad eu
oper add second approv compound portfolio iclusig cml
within inflammatori diseas space incyt advanc compound baricitinib
jak inhibitor out-licens lilli develop drug rheumatoid arthriti
ra indic baricitinib olumi approv ema februari
approv fda drug also explor indic atop
dermat system lupu erythematosu addit compound wholli own
pipelin includ small molecul inhibitor fgfr brd
thousand except share price
product revenu
total cost expens
incom oper
interest incom net
provis benefit incom tax
